FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of May 2019
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
 
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Director/PDMR Shareholding
 
 
8 May 2019 14:00 BST
 
 
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announces that, on 7 May 2019, it was notified by Marc Dunoyer, the Chief Financial Officer of the Company, that, on 7 May 2019, Mr Dunoyer purchased 8,500 Ordinary Shares of $0.25 each in the Company (Shares) at a price of £58.00 per Share.
 
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail.
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
 
a)
 
Name
 
 
Marc Dunoyer
2
 
Reason for the notification
 
a)
 
Position/status
 
 
Chief Financial Officer
b)
 
Initial notification /Amendment
 
 
Initial notification
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
 
AstraZeneca PLC
b)
 
LEI
 
 
PY6ZZQWO2IZFZC3IOL08
4
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 
a)
 
Description of the financial instrument, type of instrument
 
Identification code
 
 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 
b)
 
Nature of the transaction
 
 
Share purchase
c)
 
Price(s) and volume(s)
 
 
Price(s)
 
Volume(s)
GB£58.00
8,500
d)
 
Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 
Not applicable - single transaction
 
e)
 
Date of the transaction
 
 
7 May 2019
f)
 
Place of the transaction
 
 
XLON
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter@AstraZeneca.
 
Media Relations
 
 
Gonzalo Viña
 
+44 203 749 5916
Rob Skelding
Oncology
+44 203 749 5821
Rebecca Einhorn
Oncology
+1 301 518 4122
Matt Kent
BioPharma
+44 203 749 5906
Jennifer Hursit
Other
+44 203 749 5762
Christina Malmberg Hägerstrand
Sweden
+46 8 552 53 106
Michele Meixell
US
+1 302 885 2677
 
 
 
Investor Relations
 
 
Thomas Kudsk Larsen
 
+44 203 749 5712
Henry Wheeler
Oncology
+44 203 749 5797
Christer Gruvris
BioPharma (cardiovascular; metabolism)
+44 203 749 5711
Nick Stone
BioPharma (respiratory, renal)
+44 203 749 5716
Josie Afolabi
Other medicines
+44 203 749 5631
Craig Marks
Finance, fixed income
+44 7881 615 764
Jennifer Kretzmann
Corporate access, retail investors
+44 203 749 5824
US toll-free
 
+1 866 381 72 77
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 08 May 2019
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary